This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

Clinical efficacy & safetyPALOMA-2Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)PALOMA-2 summaryPALOMA-3Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)SafetySafety overviewPooled laboratory abnormalitiesPALOMA-2 AEsPALOMA-3 AEsSelected safety featuresIBRANCE long-term safetyGI and liver toxicitiesEffect of IBRANCE on QTc intervalElderly patientsVisceral disease patientsDose reduction effect on efficacyRW evidenceValue of RWEWhat is real-world evidence?What is the value of RWE?P-REALITY and P-REALITY XP-REALITY OverviewP-REALITY OS and rwPFSP-REALITY X OverviewP-REALITY X OS and rwPFSIRISIRIS OverviewIRIS PFS and OSPOLARIS POLARIS OverviewPOLARIS Patient-Reported OutcomesMADELINEMADELINE OverviewMADELINE Patient CharacteristicsMADELINE Patient-Reported OutcomesPalomAGEPalomAGE OverviewRWE in Older Patients with mBCP-VERIFYP-VERIFY StudyPatient-reported outcomesPALOMA-2: FACT-B scoresPALOMA-3: EORTC QLQ-C30 scoresPALOMA-3: Time to deterioration in pain symptomsDosingRecommended dosing scheduleRecommended dose modifications for AEsMonitoringOne scheduled monitoring provisionPrescribing Information ResourcesMaterials
PALOMA-2 overall survivalPatients receiving IBRANCE in combination with letrozole had a numerically longer OS compared to placebo plus letrozole, but the results were not statistically significant1PALOMA-2 OS Kaplan-Meier curve1In a 2:1 randomised, double-blind, Phase III trial of post-menopausal women with ER+/HER2- mBC (N=666)1

With a median follow-up of 7.5 years, median OS was 53.9 months (95% CI: 49.8–60.8) in the IBRANCE + letrozole arm vs 51.2 months (95% CI: 43.7–58.9) in the placebo + letrozole arm (HR=0.96; 95% CI: 0.78–1.79; p=0.3378)1

Adapted from data on file.1Data cut-off date: November 15, 2021.1
Final overall survival (secondary endpoint) analysis of PALOMA-2.1PALOMA-2 did not meet the secondary endpoint of OS (prespecified HR≤0.74)There was an 80% power to detect an OS difference between treatment arms with an HR of ≤0.74¹

Interpretation of OS in PALOMA-2 is limited by the large and disproportionate censoring of patients with missing survival data between treatment arms¹
  • A proportion of patients were no longer being followed up for survival¹
  • In the ITT analysis 21% of patients in the placebo + letrozole arm vs 13% of patients in the IBRANCE + letrozole arm were no longer being followed up for survival1
  • Patients who were no longer being followed for survival were censored at the last known date to be alive1
PALOMA-2 OS Kaplan-Meier curve excluding patients no longer being followed for survival1

In a post-hoc sensitivity analysis excluding LTFU patients, mOS with IBRANCE + letrozole was 51.6 months (95%CI: 46–57.1) vs 44.6 months with placebo + letrozole (95% CI: 37.0–52.3)1

Adapted from data on file.1Data cut-off date: November 15, 2021.1
Post-hoc sensitivity analysis excluding LTFU patients from PALOMA-2.1Statistical procedures controlling for type 1 error were not prespecified1Explore More PALOMA-3

See PALOMA-3 overall survival data

 Learn more
ITT = intent-to-treat; LTFU = lost to follow up; OS = overall survival.References:Finn RS, et al. J Clin Oncol 40, 2022 (suppl 17; abstr LBA1003)
PALOMA-2 PALOMA-3

See PALOMA-3 overall survival data

 Learn more
IBRANCE Summary of Product Characteristics Product Characteristics Loading

Legal Category: S1A
Further information is available upon request

PP-IBR-IRL-0653. August 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0832. October 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0832. October 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0832. October 2024